G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
G1 Therapeutics, Inc. (GTHX)
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
g1therapeutics.com/pages/investors/investors.htm
Company Research
Source: GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and Stillman Hanson has been named General Counsel. “We are excited to welcome John and Stillman to G1, and look forward to their contributions as we build out our commercial capabilities and expand our business development, legal and regulatory efforts,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer. “John’s experience building a world-class commercial oncology organization will be invaluable as our three clinical-stage programs move toward key clinical and regulatory milestones. Moreover, Stillman’s extensive life sciences corporate legal experience will be critical as the company continues to grow and evolve from research and development to commercialization.
Show less
Read more
Impact Snapshot
Event Time:
GTHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GTHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GTHX
News
- G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024GlobeNewswire
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
GTHX
Earnings
- 2/28/24 - Beat
GTHX
Sec Filings
- 4/12/24 - Form PRE
- 4/9/24 - Form 144
- 3/22/24 - Form 8-K
- GTHX's page on the SEC website